Gibson, Dunn & Crutcher LLP has advised Ultragenyx Pharmaceutical Inc. Davies Ward Phillips & Vineberg LLP, Latham & Watkins LLP, and Sidley Austin LLP have advised...
Ultragenyx Sells Portion of Future Crysvita Royalties to OMERS for $400 Million
X4 Pharmaceuticals Completes $155.3 Million Public Offering of Common Stock
Gibson, Dunn & Crutcher LLP has advised X4 Pharmaceuticals, and Freshfields US LLP has advised the underwriters. Dechert LLP has served as special counsel for X4...
Electra Therapeutics Secures $183 Million Series C Funding for Immunology and Cancer Therapies
Cooley has advised Electra Therapeutics, and Gibson Dunn has advised Nextech Ventures and EQT Life Sciences. Electra Therapeutics, a clinical-stage biotechnology company focused on developing therapies...
XOMA Royalty Corporation Establishes $50 Million At-the-Market Facility
Gibson Dunn has advised XOMA Royalty Corporation, and Duane Morris has advised H.C. Wainwright & Co., LLC. XOMA Royalty Corporation has established an at-the-market facility allowing...
XOMA Royalty Corporation Launches Common Stock Offering Worth $75 Million
Gibson Dunn & Crutcher has advised XOMA Royalty Corporation, and Duane Morris LLP has advised Leerink Partners LLC. XOMA Royalty Corporation has established two at-the-market facilities,...
Roche to Acquire 89bio in $3.5 Billion Merger Agreement
Sidley Austin has advised Roche, and Gibson, Dunn & Crutcher LLP has advised 89bio, Inc. Roche has entered into a definitive merger agreement to acquire 89bio,...
Dianthus Therapeutics Closes $288 Million Public Offering of Common Stock and Pre-Funded Warrants
Gibson Dunn and Goodwin Procter has advised Dianthus Therapeutics, Inc., while Cooley has represented the underwriters. Dianthus Therapeutics, Inc., a clinical-stage biotechnology company focused on antibody...
Arrowhead and Novartis Sign Global Licensing Agreement for Preclinical RNA Therapy
Gibson Dunn has advised Arrowhead Pharmaceuticals on the deal. Arrowhead Pharmaceuticals and Novartis have entered into a global license and collaboration agreement concerning ARO-SNCA, Arrowhead’s preclinical...
Royalty Pharma Acquires Royalty Interest in Amgen’s Imdelltra from BeOne Medicines for Up to $950 Million
Gibson Dunn & Crutcher, Dechert and Maiwald have advised Royalty Pharma. Royalty Pharma plc has acquired a royalty interest in Amgen’s Imdelltra from BeOne Medicines for...
Mural Oncology plc to Be Acquired by XRA 5 Corp (XOMA Royalty Corporation)
Arthur Cox has advised Mural Oncology plc. Gibson Dunn has advised XOMA Royalty Corporation and its subsidiary XRA 5 Corp. Mural Oncology plc has entered into...
XOMA Royalty to Acquire LAVA Therapeutics in Cash and Contingent Value Rights Deal
Gibson, Dunn & Crutcher LLP and Loyens & Loeff N.V. have advised XOMA Royalty Corporation on the transaction, while Cooley LLP and NautaDutilh N.V. as its...
RTW Investments Leads $85 Million Equity Offering by Aquestive Therapeutics
Gibson Dunn has advised RTW Investments, LP. , Dechert has advised Aquestive Therapeutics, Inc. and Cooley has advised the underwriters. RTW Investments, LP has acquired common...